Evidence map›Paper›PMID 42146855›Full record

ArticleBrain communications2026

Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes.

Kelly Ho, Ofosu Adjei-Afriyie, Ricardo Carmona-Martinez, Rohan Ray, Daniel O'Neil, Joshua Zeldin, Julien Oury, Lieselot De Clercq, Steven J Burden, Bernhardt Vankerckhoven and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kelly HoChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.ORCID https://orcid.org/0009-0006-4364-4772
Ofosu Adjei-AfriyieChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.
Ricardo Carmona-MartinezChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.
Rohan RayChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.
Daniel O'NeilChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.
Joshua ZeldinChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.
Julien OuryTevard Biosciences, Cambridge, MA 02139, USA.
Lieselot De Clercqargenx, Zwijnaarde, 9052 Ghent, Belgium.
Steven J BurdenDepartment of Neurology, Massachusetts General Hospital, Harvard University, Boston, MA 02114, USA.
Bernhardt Vankerckhovenargenx, Zwijnaarde, 9052 Ghent, Belgium.
Roeland Vanhauwaertargenx, Zwijnaarde, 9052 Ghent, Belgium.
Sally SpendiffChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.ORCID https://orcid.org/0000-0001-9579-3514
Hanns LochmüllerChildren's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital myasthenic syndromes (CMS) are a group of rare disorders characterized by fatigable muscle weakness and caused by impaired neuromuscular junction (NMJ) function. CMS symptoms are highly variable, but it can be detrimental and lead to death. There are over 40 different genetic subtypes, including

Indexed as

congenital myasthenic syndromesneuromuscular diseaseneuromuscular junctionpreclinical trial

Identifiers

PMID42146855
PMCPMC13174946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.